Docoh
Loading...

SYN Synthetic Biologics

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Company profile

Ticker
SYN
Exchange
CEO
Steven A. Shallcross
Employees
Incorporated
Location
Fiscal year end
Former names
ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC
SEC CIK
IRS number
133808303

SYN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 76.89M 76.89M 76.89M 76.89M 76.89M 76.89M
Cash burn (monthly) (positive/no burn) (positive/no burn) 845.67K 805.75K 1.11M 878K
Cash used (since last report) n/a n/a 3.45M 3.29M 4.53M 3.59M
Cash remaining n/a n/a 73.43M 73.6M 72.36M 73.3M
Runway (months of cash) n/a n/a 86.8 91.3 65.2 83.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 May 21 Steven A Shallcross Common Stock Buy Aquire P No No 0.4919 50,000 24.6K 100,000
30 Dec 20 Steven A Shallcross Stock Options Common Stock Grant Aquire A No No 0.417 450,000 187.65K 450,000
30 Dec 20 John J Monahan Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000
30 Dec 20 Wolf Jeffrey Alan Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000
30 Dec 20 Kraws Jeffrey J Stock Options Common Stock Grant Aquire A No No 0.417 150,000 62.55K 150,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 34 24 +41.7%
Opened positions 14 5 +180.0%
Closed positions 4 4
Increased positions 11 5 +120.0%
Reduced positions 1 3 -66.7%
13F shares
Current Prev Q Change
Total value 8.29M 2.72M +205.3%
Total shares 11.87M 7.16M +65.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
BLK Blackrock 2.35M $1.6M +6046.0%
Custodian Ventures 2.22M $1.96M +13.2%
Vanguard 2.01M $1.37M +5436.1%
Iroquois Capital Management 1.13M $433K 0.0%
MSD Partners 960.68K $655K NEW
Geode Capital Management 860.42K $586K +4779.6%
UBS UBS Group AG - Registered Shares 576.93K $393K NEW
Citadel Advisors 539.12K $368K NEW
VIRT Virtu Financial 466.7K $318K +347.1%
NTRS Northern Trust 246.54K $168K +1706.7%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 2.35M +2.31M +6046.0%
Hudson Bay Capital Management 0 -2.22M EXIT
Vanguard 2.01M +1.98M +5436.1%
Renaissance Technologies 0 -1.24M EXIT
MSD Partners 960.68K +960.68K NEW
Geode Capital Management 860.42K +842.79K +4779.6%
UBS UBS Group AG - Registered Shares 576.93K +576.93K NEW
Citadel Advisors 539.12K +539.12K NEW
VIRT Virtu Financial 466.7K +362.32K +347.1%
Custodian Ventures 2.22M +260K +13.2%

Financial report summary

?
Management Discussion
  • General and administrative expenses increased by 2% to approximately $1.42 million for the three months ended March 31, 2021, from approximately $1.39 million for the three months ended March 31, 2020. This increase is primarily due to higher insurance costs, audit fees, and legal costs offset by a reduction in patent related legal fees, consulting fees and travel expense. The charge related to stock-based compensation expense was $82,000 for the three months ended March 31, 2021, compared to $65,000 the three months ended March 31, 2020.
  • Research and development expenses decreased by 32% to approximately $1.1 million for the three months ended March 31, 2021, from approximately $1.6 million for the three months ended March 31, 2020. This decrease is primarily the result of lower indirect program costs for the three months ended March 31, 2021, including salary and related expense reductions, a decrease in manufacturing costs for SYN-020 and market research. In addition, as a result of the global COVID-19 pandemic, our clinical development partner (Washington University) reduced their operating capacity during 2021 to include only essential activities as part of their pandemic response, which delayed the start of our clinical trial, resulting in lower clinical trial expenses for the quarter. The research and development costs incurred during the quarter were primarily related to our Phase 1a clinical trial of SYN-020 and the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients.  The charge related to stock-based compensation expense was $19,000 for the three months ended March 31, 2021, compared to $18,000 related to stock-based compensation expense for the three months ended March 31, 2020.
  • Other income was $347 for the three months ended March 31, 2021, compared to other income of $38,000 for the three months ended March 31, 2020. Other income for the three months ended March 31, 2021 and 2020 is primarily comprised of interest income.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abated, accurately, aforementioned, AGP, April, ATM, Australia, authorized, began, begun, biotechnology, blocker, book, clause, climate, competitive, declined, discernable, disconnected, extreme, facilitating, facility, fire, gluten, hereof, inability, inconsistent, induce, inducement, inflated, instability, insufficient, issuable, law, leave, liver, lose, losing, MAD, Nevada, past, pathway, play, political, Practice, predominantly, prevalent, prohibit, put, reaction, remeasurement, restated, role, Secretary, squeeze, stability, steadily, stemming, streamlined, superior, terrorism, Topic, underway, unissued, unpaid, volume, war, weather
Removed: abdominal, absenteeism, accomplished, achieve, acted, adaptive, Aid, altogether, amending, amortized, assure, assured, avoid, baseline, beneficially, bloating, breath, Bulletin, capitalization, capsule, carryback, classification, cleared, collaborator, combined, communication, competing, composition, comprehensive, comprise, conclusion, confident, Confirmed, convene, criterion, decide, decision, deduct, deficiency, delisted, delisting, design, desire, diagnosed, difficult, dollar, doubt, downturn, economy, effort, eligibility, eligible, enable, enacted, enforcing, enrolling, establish, established, eventually, execute, expenditure, Exploratory, extend, fact, fail, fell, fewer, firm, fiscal, frequency, Fundamental, furlough, generating, geographic, group, Guide, halt, harmed, ill, impacting, implementing, Importantly, imposed, improvement, inclusive, infected, inform, infrastructure, intend, interruption, investigating, issuer, junior, large, light, limit, liquid, list, listed, longer, lot, manager, mandate, meaningful, Medically, medication, nationwide, noted, obtaining, occur, office, OTC, outlined, outlining, overhead, package, pain, parity, partial, participate, partnering, people, periodically, postponed, postponing, previously, proceeding, prospective, prove, proximity, pursuing, pursuit, quality, quotation, rapidly, receiving, recommence, recommended, recover, recoverability, recruit, recruiting, recruitment, redesigned, reflect, regain, registrational, Regulation, Relief, removal, removing, rescue, runway, satisfy, schedule, Science, screen, screened, screening, Section, securing, selected, serving, shelf, shipping, sooner, specifically, spend, spending, spent, sponsored, statin, stating, stool, substantially, successful, suffer, sustained, sweeping, temporarily, testing, timeline, transport, treating, twelve, unamortized, unexpected, unintended, utilization, utilize, vancomycin, variety, visit, weekly, widespread, wrong